Ivosidenib as Post-HSCT Maintenance for AML

NCT06707493 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

IDH1 Mutation
Acute Myeloid Leukemia (AML)
Hematopoietic Stem Cell Transplant (HSCT)

Interventions

DRUG: Ivosidenib
DRUG: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]